Table 3.

Summary of Clinical Improvement for a Minimum Duration of 2 Months in Patients With Refractory CLL Treated With Ofatumumab

Improvement in Clinical Parameters	FA-ref			BF-ref
	No. of Patients With Abnormal Clinical Parameters at Baseline	Patients With Improvement From Baseline to Week 24		No. of Patients With Abnormal Clinical Parameters at Baseline	Patients With Improvement From Baseline to Week 24
		No.	%		No.	%
Complete resolution of constitutional symptoms	31	15	48	46	29	63
Complete resolution of lymphadenopathy (nodes < 1 cm)	55	9	16	74	8	11
Complete resolution of splenomegaly	30	14	47	46	16	35
Complete resolution of hepatomegaly	18	9	50	21	11	52
Normalization of neutrophil count (from < 1.5 × 109/L to ≥ 1.5 × 109/L)	19	1	5	17	5	29
Improvement in hemoglobin level (from ≤ 11.0 g/dL to > 11.0 g/dL)	26	8	31	42	11	26
Improvement in platelet count (from ≤ 100 × 109/L to > 50% increase or > 100 × 109/L)	29	12	41	44	17	39

Abbreviations: CLL, chronic lymphocytic leukemia; FA-ref, fludarabine and alemtuzumab refractory; BF-ref, bulky fludarabine refractory.